Phase 1 12 trials
Phase 1
NCT04023669 Aug 2019 → May 2023 brain cancer , medulloblastoma non-WNT/non-SHH group 3 , medulloblastoma non-WNT/non-SHH group 4 St. Jude Children's Research Hospital
Completed
No outcome recorded
Phase 1
NCT03735446 Jan → Mar 2019 acute myeloid leukemia , myelodysplastic syndrome Dana-Farber Cancer Institute
Terminated
No outcome recorded
Phase 1
NCT03495323 May 2018 → Feb 2021 cancer Dana-Farber Cancer Institute
Completed
No outcome recorded
Phase 1
NCT03057145 Mar 2017 → Feb 2020 cancer Geoffrey Shapiro, MD, PhD
Completed
No outcome recorded
Phase 1
NCT02808650 Feb 2017 → Dec 2019 central nervous system cancer , childhood malignant neoplasm , refractory malignant neoplasm Children's Oncology Group
Completed
No outcome recorded
Phase 1
NCT02778126 Sep 2016 → Apr 2017 cancer of unknown primary site Eli Lilly and Company
Completed
No outcome recorded
Phase 1
NCT02860780 Aug 2016 → May 2017 cancer of unknown primary site , colorectal cancer , metastatic malignant neoplasm , non-small cell lung carcinoma Eli Lilly and Company
Completed
No outcome recorded
Phase 1
NCT02649764 May 2016 → Jul 2022 acute myeloid leukemia , chronic myelomonocytic leukemia , myelodysplastic syndrome M.D. Anderson Cancer Center
Completed
No outcome recorded
Phase 1
NCT02555644 Feb 2016 → Jan 2019 head and neck neoplasm Eli Lilly and Company
Completed
No outcome recorded
Phase 1
NCT02514603 Oct 2015 → Apr 2017 neoplasm Eli Lilly and Company
Completed
No outcome recorded
Phase 1
NCT02124148 Jun 2014 → Feb 2020 breast cancer , colorectal neoplasm , metastatic neoplasm Eli Lilly and Company
Completed
No outcome recorded
Phase 1
NCT01115790 Feb 2010 → Jan 2016 anal squamous cell carcinoma , head and neck squamous cell carcinoma , non-small cell squamous lung carcinoma Eli Lilly and Company
Completed
No outcome recorded
Show 2 more trials Phase 1/2 1 trial
Phase 1/2
NCT04095221 Sep 2019 → Feb 2025 desmoplastic small round cell tumor , rhabdomyosarcoma Memorial Sloan Kettering Cancer Center
Completed
No outcome recorded
Phase 2 7 trials
Phase 2
NCT06597565 Sep 2024 → Aug 2028 expected head and neck squamous cell carcinoma H. Lee Moffitt Cancer Center and Research Institute
Recruiting
No outcome recorded
Phase 2
NCT05548296 Aug 2022 → May 2027 expected endometrium adenocarcinoma Acrivon Therapeutics
Recruiting
No outcome recorded
Phase 2
NCT04032080 Sep 2019 → Jun 2022 triple-negative breast carcinoma Baylor Research Institute
Completed
No outcome recorded
Phase 2
NCT03414047 Apr 2018 → Jun 2019 ovarian cancer Eli Lilly and Company
Completed
No outcome recorded
Phase 2
NCT02873975 Oct 2016 → Sep 2020 cancer of unknown primary site Dana-Farber Cancer Institute
Completed
No outcome recorded
Phase 2
NCT02735980 May 2016 → Jul 2017 small cell lung carcinoma Eli Lilly and Company
Completed
No outcome recorded
Phase 2
NCT02203513 Jan 2015 → Aug 2021 breast cancer , ovarian cancer , prostate cancer National Cancer Institute (NCI)
Terminated
No outcome recorded